Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.
Counterpoint Tactical Equity A CPAEX
- NAV / 1-Day Return 18.37 / +0.05 %
- Total Assets 102.5 Mil
-
Adj. Expense Ratio
- Expense Ratio 2.030%
- Distribution Fee Level High
- Share Class Type Front Load
- Category Long-Short Equity
- Investment Style Small Blend
- Min. Initial Investment 5,000
- Status Open
- TTM Yield 1.93%
- Turnover 391%
USD | NAV as of Apr 22, 2024 | 1-Day Return as of Apr 22, 2024, 10:10 PM GMT+0
Morningstar’s Analysis CPAEX
Will CPAEX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 8.6
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Spdr Sp 500 Etf Long | 50.15 | 34.4 Mil | — |
Jpm Ind Long 2 | 37.03 | 25.4 Mil | — |
Jpm Ind Long 1 | 35.63 | 24.4 Mil | — |
Fidelity Inv MM Treasury I | 18.10 | 12.4 Mil | Cash and Equivalents |
United States Treasury Bills 0% | 15.26 | 10.5 Mil | Government |
Counterpoint Quantitative Equity ETF | 9.98 | 6.8 Mil | — |
United States Treasury Bills 0% | 7.22 | 5.0 Mil | Government |
S&P Emini 1St Wee Jan24c 1Ef4c 4570 Index | 1.22 | 838,338 | — |
Us Dollar Future | 1.06 | 725,799 | Cash and Equivalents |
RxSight Inc | 0.39 | 269,741 | Healthcare |